Lung Stereotactic Radiation Therapy for Patients With Non-small Cell Lung Cancer and Other Cancers
SBRT is an adaptation of the principles and experience gained from stereotactic brain RT.
SBRT was developed in the early 90s at the Karolinska Institute in Stockholm, Sweden, and is
used as an accepted alternative of treatment for patients with early stage lung cancer in
many centers in Japan and a number of centers in Germany,USA and elsewhere. It is also now
being used for patients who have lung metastases and extra-thoracic disease (primary or
metastatic). Many reports indicate excellent local control (80-90% or higher) and minimal
toxicity in well selected patients treated with thoracic SBRT.
SBRT has traditionally had the following features:
1. High doses of radiation, usually in a few large fractions (it is "hypofractionated"
compared with standard radiotherapy schedules)
2. Multiple radiation beams coming from different directions in the same plane
('co-planar' beams) as well as from different directions and different planes relative
to the patient's body ('non-coplanar' beams)
3. Stereotactic beam placement, in that it is guided by a set of coordinates These
coordinates are defined in relationship to the precise location of the tumor,
determined from medical imaging (e.g. CT, MRI), rather than to a set of external marks
(tattoos) or anatomical landmarks (such as bony structures)
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine local control in patients treated with SBRT.
John Cho, MD
University Health Network, Princess Margaret Hospital
Canada: Ethics Review Committee
UHN REB 05-0951-C